http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI1102001-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b2af763e46a5b8ebfd6d8b9729cd9a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ccfe23291f627258df6a6bb93c0fb31 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-714 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415 |
| filingDate | 2011-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0040d07b2da1e8b0ae1f457badba203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f8321b9394537042185c398fa61fe92 |
| publicationDate | 2013-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI1102001-A2 |
| titleOfInvention | pharmaceutical composition for anti-inflammatory, myorelaxant and analgesic |
| abstract | PHARMACEUTICAL COMPOSITION FOR ANTI-INFLAMMATORY, MIORRELAXANT AND ANALGESIC The invention relates to a pharmaceutical composition intended for use as an anti-inflammatory, myorelaxant and analgesic for joint pain, rheumatism, spine, arthritis, arthritis and other pain resulting from inflammatory processes. The pharmaceutical domain comprises the combination of five drugs: famotidine, piroxicam, dexamethasone, cyanocobalamin and orphenadrine. The association of famotidine with the formulation promotes a protective effect of the gastroduodenal mucosa in patients using anti-inflammatory drugs such as piroxicam and dexamethasone. Famotidine is a drug with a favorable profile, taking into account its tolerability, potency and safety compared to other anti H2 drugs and other drugs commonly used to inhibit gastric acid secretion. The drug hardly undergoes hepatic metabolism, is weakly bound to plasma proteins, has a rapid onset of action, and has no relevant undesirable effects. The pharmaceutical composition has the following formulation: - piroxicam 20mg - famotidine 20 mg - dexamethasone 0.1 mg - cyanocobalamin 2500 mcg - orphenadrine 35 mg - excipient qsp 100 mg |
| priorityDate | 2011-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.